A5012715289- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Autoimmune Bullous Skin Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical studies and practices
- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- Cytokine Signaling Pathways and Interactions
- Urticaria and Related Conditions
- Nail Diseases and Treatments
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Antifungal resistance and susceptibility
- Synthesis and biological activity
- Food Allergy and Anaphylaxis Research
- Monoclonal and Polyclonal Antibodies Research
- Biosimilars and Bioanalytical Methods
- Immunodeficiency and Autoimmune Disorders
- Mast cells and histamine
- T-cell and B-cell Immunology
- Complementary and Alternative Medicine Studies
- Spondyloarthritis Studies and Treatments
- Celiac Disease Research and Management
- Autoimmune and Inflammatory Disorders Research
- Retinoids in leukemia and cellular processes
- Therapeutic Uses of Natural Elements
VA New Jersey Health Care System
2016-2025
Navitas Systems (United States)
2024-2025
Windsor Dermatology
2014-2024
Icahn School of Medicine at Mount Sinai
2020-2024
UCB Pharma (United States)
2022
American Academy of Dermatology
2022
Hudson Institute
2021
Bristol-Myers Squibb (Germany)
2021
Boehringer Ingelheim (India)
2021
Bristol-Myers Squibb (Switzerland)
2021
Early clinical studies suggested that the anti-interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in treatment of psoriasis.In two phase 3 (AMAGINE-2 and AMAGINE-3), patients with moderate-to-severe psoriasis were randomly assigned to receive (210 mg or 140 every 2 weeks), ustekinumab (45 for a body weight ≤100 kg 90 >100 kg), placebo. At week 12, receiving again maintenance dose 210 weeks weeks, 4 8 weeks; continued 12 placebo received weeks. The primary aims evaluate...
BackgroundDeucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, inhibits cytokine signaling in psoriasis pathogenesis.ObjectiveThe objective of this study was to demonstrate deucravacitinib superiority versus placebo and apremilast moderate severe plaque based on ≥75% reduction from baseline Psoriasis Area Severity Index a static Physician's Global Assessment score 0 (clear) or 1 (almost clear) with ≥2-point improvement at week 16.MethodsPOETYK second trial...
Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-17A and interleukin-17F. The efficacy safety of bimekizumab as compared with the tumor necrosis factor inhibitor adalimumab in patients moderate-to-severe plaque psoriasis have not been extensively examined.We randomly assigned 1:1:1 ratio to receive subcutaneous at dose 320 mg every 4 weeks for 56 weeks; 16 weeks, then 8 56; or 40 2 24 followed by week 56. primary end points were 90% greater reduction from...
Tapinarof cream is a topical aryl hydrocarbon receptor-modulating agent under investigation for the treatment of psoriasis. modulates expression interleukin-17 and skin-barrier proteins filaggrin loricrin.We conducted two identical phase 3 randomized trials tapinarof in patients with mild-to-severe plaque Adults baseline Physician's Global Assessment (PGA) score 2 (mild) to 4 (severe) (on scale from 0 4, higher scores indicating more severe psoriasis) percent total body-surface area affected...
Importance Once-daily roflumilast cream, 0.3%, a potent phosphodiesterase 4 inhibitor, demonstrated efficacy and was well tolerated in phase 2b trial of patients with psoriasis. Objective To evaluate the applied once daily for 8 weeks 2 trials plaque Design, Setting, Participants Two 3, randomized, double-blind, controlled, multicenter (DERMIS-1 [trial 1; n = 439] DERMIS-2 2; 442]) were conducted at 40 centers (trial 1) 39 2) US Canada between December 9, 2019, November 16, 2020, 23,...
Lebrikizumab (LEB), a high-affinity monoclonal antibody targeting interleukin (IL)-13, demonstrated efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD) during 16 weeks of monotherapy phase 2b trial, two 52-week 3 trials.To evaluate LEB combined low- to mid-potency topical corticosteroids (TCS) AD.The ADhere trial was 16-week randomized, double-blinded, placebo (PBO)-controlled, multicenter, clinical conducted from February 3, 2020, September 16, 2021. The study at...
A task force of the National Psoriasis Foundation Medical Board was convened to evaluate current severity criteria mild, moderate, and severe psoriasis make recommendations concerning a 2-tiered categorization based on clinical practice related intent treat.This volunteer force, led by David M. Pariser, MD, included Jerry Bagel, Joel Gelfand, MSCE, Neil J. Korman, PhD, Christopher T. Ritchlin, Bruce E. Strober, Abby S. Van Voorhees, Melodie Young, MSN, RN, ANP. Meetings were held...
Patients with psoriasis value rapid and complete skin clearance. No head‐to‐head studies have focused on early responses to interleukin (IL)‐17 vs. IL‐23 inhibitors. To compare clearance by the IL‐17A inhibitor ixekizumab IL‐23p19 guselkumab. IXORA‐R, a 24‐week, randomized, double‐blinded study, enrolled adults moderate‐to‐severe plaque [static Physician's Global Assessment of Disease (sPGA) score ≥ 3, Psoriasis Area Severity Index (PASI) 12, 10% body surface area]. were randomized (1 : 1)...
Background: An aerosol foam formulation of fixed combination calcipotriene 0.005% (as hydrate; Cal) plus betamethasone dipropionate 0.064% (BD) was developed to improve psoriasis treatment. Objectives: To compare the efficacy and safety Cal/BD with ointment after 4 weeks. Methods: In this Phase II, multicenter, investigator-blind, 4-week trial, adult patients vulgaris were randomized foam, ointment, vehicle or (3:3:1:1). The primary endpoint proportion at week who achieved treatment success...
BackgroundModerate-to-severe scalp psoriasis has not been evaluated in prospective trials of patients without moderate-to-severe body psoriasis.ObjectiveEvaluate the efficacy and safety secukinumab psoriasis.MethodsIn this 24-week, double-blind, phase 3b study, 102 were randomized 1:1 to subcutaneous 300 mg or placebo at baseline, weeks 1, 2, 3, then every 4 from week 20. The primary variable was 90% improvement Psoriasis Scalp Severity Index (PSSI 90) score baseline 12.ResultsAt 12, PSSI 90...
Plaque psoriasis affects children and adults, but treatment options for paediatric are limited. To evaluate the efficacy safety of ixekizumab (IXE), a high‐affinity monoclonal antibody that selectively targets interleukin‐17A, moderate‐to‐severe psoriasis. In randomized, double‐blind, placebo‐controlled, phase III study (IXORA‐PEDS), patients aged 6 to < 18 years with plaque were randomized 2 : 1 weight‐based dosing IXE every 4 weeks (IXE Q4W, n = 115) or placebo (n 56) through week 12,...
Objective: To determine the efficacy, safety, and sustainability of response to adalimumab therapy for moderate severe chronic plaque psoriasis involving hands and/or feet.Design: Sixteen-week, randomized, double-blind, placebo-controlled evaluation feet with a 12-week open-label extension (Randomized Controlled Evaluation Adalimumab in Treatment Chronic Plaque Psoriasis Hands Feet [REACH]).Setting: Multicenter outpatient study United States Canada.Participants: Patients on Physician's...
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated superior efficacy to ustekinumab in the phase 3b CLEAR study of moderate severe plaque psoriasis. Here, we report 16-week results from CLARITY, second head-to-head trial comparing secukinumab with ustekinumab.In CLARITY study, patients were randomized 1:1 receive subcutaneous 300 mg or per label. The co-primary objectives demonstrate superiority over at Week 12 relation proportion (1) 90% more improvement...
In the U.S.A., an Investigator's Global Assessment (IGA) score of ≤ 1 (clear or almost clear skin) has been standard measure in regulatory outcomes for registration clinical trials atopic dermatitis (AD), including those supporting recent approval dupilumab. To evaluate treatment effect dupilumab patients with IGA > at end treatment, using other validated outcome measures AD signs, symptoms and quality life. LIBERTY SOLO 2 were two 16‐week, randomized, double‐blind enrolling adult...
Background Obesity is a common comorbidity of psoriasis and can attenuate response to biologic treatment. Objectives To investigate the efficacy, safety tolerability secukinumab 300 mg every 2 weeks (Q2W) vs. 4 (Q4W) in patients with higher bodyweight. Methods In this multicentre, double-blind, parallel-group trial, 331 moderate-to-severe chronic plaque weighing ≥ 90 kg were randomized receive Q2W or Q4W. Patients who did not achieve Psoriasis Area Severity Index (PASI) at week 16 on Q4W...